Patients treated with A9 biolimus eluting stent with biodegradable polymer (Nobori, Terumo) can receive only six months of dual antiplatelet therapy (DAPT) with no increase in adverse events, compared against more prolonged treatments.
The net adverse clinical and cerebrovascular events that included all cause death, MI, cerebrovascular events and major bleeding was:
- 1.92% for patients undergoing 6 month DAPT
- 1.45% for patients undergoing 18 month DAPT
Despite the non-inferiority of 6 month DAPT, results should be interpreted with caution since, for one thing, SCA patients received clopidogrel when, in Europe, the antiplatelet most commonly used is by far ticagrelor. In addition, guidelines clearly recommend 12 month DAPT for this clinical scenario.
The NIPPON included 1,391 patients treated for 18 months with aspirin/clopidogrel and 1,381 patients treated for 6 months with identical scheme. 30% of this population were patients undergoing ACS.
Original Title: Six months versus 18 months dual antiplatelet treatment for patients undergoing bioresorbable polymer and abluminal-coated DES deployment: NIPPON randomized study.
Presenter: Nakamura M.
We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.
